Success Metrics

Clinical Success Rate

78.6%

Based on 22 completed trials

Completion Rate

79%(22/28)

Active Trials

4(10%)

Results Posted

91%(20 trials)

Terminated

6(15%)

Phase Distribution

Ph early_phase_1

Ph not_applicable

33%

Ph phase_1

13%

Ph phase_2

26%

Ph phase_3

10%

Ph phase_4

15%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution39 total trials

Early Phase 1First-in-human

1(2.6%)

Phase 1Safety & dosage

5(12.8%)

Phase 2Efficacy & side effects

10(25.6%)

Phase 3Large-scale testing

4(10.3%)

Phase 4Post-market surveillance

6(15.4%)

N/ANon-phased studies

13(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.0%

22 of 31 finished

Non-Completion Rate

29.0%

9 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(22)

Terminated(9)

Other(4)

Detailed Status

Completed22

Terminated6

unknown3

Withdrawn3

Recruiting3

Suspended1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

78.6%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (2.6%)

Phase 15 (12.8%)

Phase 210 (25.6%)

Phase 34 (10.3%)

Phase 46 (15.4%)

N/A13 (33.3%)

Trials by Status

suspended13%

unknown38%

terminated615%

completed2256%

withdrawn38%

active_not_recruiting13%

recruiting38%

Recent Activity

4 active trials

Showing 5 of 39

recruitingphase_2

Clinical Trials (39)

Showing 20 of 39 trialsScroll for more

NCT06629077Phase 2

Brain Blood Vessel Responses to Changes in Blood Flow

Recruiting

NCT03539614Phase 3

Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests

Active Not Recruiting

NCT06629090Phase 2

Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort

Recruiting

NCT04793685Phase 2

Prazosin for Alcohol Use Disorder With Withdrawal Symptoms

Recruiting

NCT03997864Phase 4

Administration of Prazosin to Prevent PTSD in Adult Women After Sexual Assault

Withdrawn

NCT02965027Phase 4

Prazosin for Post-Concussive Headaches

Completed

NCT05189977Phase 1

A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

Terminated

NCT04365257Phase 2

Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)

Terminated

NCT03710642Phase 2

Prazosin for Agitation in Alzheimer's Disease

Completed

NCT03894345Phase 1

Prazosin Use in Adults With Anxiety Disorders

Suspended

NCT02655354Not Applicable

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

Completed

NCT02322047Phase 2

Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders

Completed

NCT01518972Phase 2

Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder

Completed

NCT00744055Phase 3

Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).

Completed

NCT02193256Early Phase 1

Varenicline + Prazosin for Heavy Drinking Smokers

Completed

NCT03416569Not Applicable

Effects of Prazosin on the Attention-Enhancing Effects of Nicotine

Withdrawn

NCT02382848Not Applicable

Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD

Completed

NCT02431936Phase 2

Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress

Completed

NCT02966340Phase 1

Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment

Completed

NCT02199652Phase 4

Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)

Completed

Drug Details

Intervention Type: DRUG
Total Trials: 39